Natural lipophilic inhibitors of mitochondrial complex I are candidate toxins for sporadic neurodegenerative tau pathologies

Experimental Neurology

Volumn 220, Issue 1, 2009, Pages 133-142

  Höllerhage, Matthias ^a   Matusch, Andreas ^a   Champy, Pierre ^b   Lombès, Anne ^c   Ruberg, Merle ^d,e   Oertel, Wolfgang H ^a   Höglinger, Günter U ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b UNIVERSITÉ PARIS SUD   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d INSERM   (France)

^e SORBONNE UNIVERSITÉ   (France)

Author keywords

Adenosine triphosphate; Environmental neurotoxin; Microtubule associated protein tau; Mitochondrial complex I; Neurodegeneration

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANNONACIN; ANNONACINONE; AUREOTHAN; BULLATACIN; CAPSAICIN; DEGUELIN; ENZYME INHIBITOR; FENAZAQUIN; ISOANNONACIN; NEUROTOXIN; PAPAVERINE; PHENALAMIDE A2; PIERICIDIN A; PIERICIDIN C1; PIERICIDIN C2; PIERICIDIN C3; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); RHEIN; ROTENONE; SOLAMIN; SOOTEPENSIN A; SOOTEPENSIN B; SQUAMOCIN; TAU PROTEIN; THIANGAZOLE; TONKINESIN C; TONKININ C; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; EMBRYO; ENZYME INHIBITION; IC 50; LIPOPHILICITY; NERVE CELL CULTURE; NERVE CELL NECROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RAT; RISK ASSESSMENT; RISK FACTOR; TAUOPATHY;

EID: 70349798628     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2009.08.004     Document Type: Article

References (55)

1. Albers D.S., and Beal M.F. Mitochondrial dysfunction in progressive supranuclear palsy. Neurochem. Int. 40 (2002) 559-564
2. Ballard P.A., Tetrud J.W., and Langston J.W. Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases. Neurology 35 (1985) 949-956
3. Bermejo A., Figadere B., Zafra-Polo M., Barrachina I., Estornell E., and Cortes D. Acetogenins from Annonaceae: recent progress in isolation, synthesis and mechanisms of action. Nat. Prod. Rep. 22 (2005) 269-303
4. Betarbet R., Sherer T.B., MacKenzie G., Garcia-Osuna M., Panov A.V., and Greenamyre J.T. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. 3 (2000) 1301-1306
5. Caparros-Lefebvre D., Sergeant N., Lees A., Camuzat A., Daniel S., Lannuzel A., Brice A., Tolosa E., Delacourte A., and Duyckaerts C. Guadeloupean parkinsonism: a cluster of progressive supranuclear palsy-like tauopathy. Brain 125 (2002) 801-811
6. Champy P., Höglinger G.U., Féger J., Gleye C., Hocquemiller R., Laurens A., Guérineau V., Laprévote O., Medja F., Lombès A., Michel P.P., Lannuzel A., Hirsch E.C., and Ruberg M. Annonacin, a lipophilic inhibitor of mitochondrial complex I, induces nigral and striatal neurodegeneration in rats: possible relevance for atypical parkinsonism in Guadeloupe. J. Neurochem. 88 (2004) 63-69
7. Champy P., Melot A., Guérineau Eng V., Gleye C., Fall D., Höglinger G.U., Ruberg M., Lannuzel A., Laprévote O., Laurens A., and Hocquemiller R. Quantification of acetogenins in Annona muricata linked to atypical parkinsonism in Guadeloupe. Mov. Disord. 20 (2005) 1629-1633
8. Champy P., Escobar-Khondiker M., Bajin I., Yamada E., Lannuzel A., Laprevote O., Ruberg M., and Hoglinger G. Atypical parkinsonism induced by Annonaceae: where are we yet?. Planta Med. 74 (2008) 936-937
9. Chirichigno J.W., Manfredi G., Beal M.F., and Albers D.S. Stress-induced mitochondrial depolarization and oxidative damage in PSP cybrids. Brain Res. 951 (2002) 31-35
10. Dawid W. Biology and global distribution of myxobacteria in soils. FEMS Microbiol. Rev. 24 (2000) 403-427
11. Degli Esposti M. Inhibitors of NADH-ubiquinone reductase: an overview. Biochim. Biophys. Acta 1364 (1998) 222-235
12. Escobar-Khondiker M., Höllerhage M., Muriel M., Champy P., Bach A., Depienne C., Respondek G., Yamada E.S., Lannuzel A., Yagi T., Hirsch E.C., Oertel W.H., Jacob R., Michel P.P., Ruberg M., and Höglinger G.U. Annonacin, a natural mitochondrial complex I inhibitor, causes tau pathology in cultured neurons. J. Neurosci. 27 (2007) 7827-7837
13. Friedrich T., van Heek P., Leif H., Ohnishi T., Forche E., Kunze B., Jansen R., Trowitzsch-Kienast W., Höfle G., Reichenbach H., et al. Two binding sites of inhibitors in NADH: ubiquinone oxidoreductase (complex I). Relationship of one site with the ubiquinone-binding site of bacterial glucose:ubiquinone oxidoreductase. Eur. J. Biochem. 219 (1994) 691-698
14. Goedert M., Ghetti B., and Spillantini M.G. Tau gene mutations in frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17). Their relevance for understanding the neurogenerative process. Ann. N.Y. Acad. Sci. 920 (2000) 74-83
15. Gutman M., Singer T.P., and Casida J.E. Studies on the respiratory chain-linked reduced nicotinamide adenine dinucleotide dehydrogenase. XVII. Reaction sites of piericidin A and rotenone. J. Biol. Chem. 245 (1970) 1992-1997
16. Haag H.B. Toxicological studies of Derris elliptica and its constituents. I. Rotenone. J. Pharmacol. Exp. Ther. 43 (1931) 193-208
17. Höglinger G.U., Féger J., Prigent A., Michel P.P., Parain K., Champy P., Ruberg M., Oertel W.H., and Hirsch E.C. Chronic systemic complex I inhibition induces a hypokinetic multisystem degeneration in rats. J. Neurochem. 84 (2003) 491-502
18. Höglinger G.U., Lannuzel A., Khondiker M.E., Michel P.P., Duyckaerts C., Féger J., Champy P., Prigent A., Medja F., Lombes A., Oertel W.H., Ruberg M., and Hirsch E.C. The mitochondrial complex I inhibitor rotenone triggers a cerebral tauopathy. J. Neurochem. 95 (2005) 930-939
19. Hollingworth R.M., Ahammadsahib K.I., Gadelhak G., and McLaughlin J.L. New inhibitors of complex I of the mitochondrial electron transport chain with activity as pesticides. Biochem. Soc. Trans. 22 (1994) 230-233
20. Javitch J.A., D'Amato R.J., Strittmatter S.M., and Snyder S.H. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc. Natl. Acad. Sci. U. S. A. 82 (1985) 2173-2177
21. Kahlert S., Zündorf G., and Reiser G. Detection of de- and hyperpolarization of mitochondria of cultured astrocytes and neurons by the cationic fluorescent dye rhodamine 123. J. Neurosci. Methods 171 (2008) 87-92
22. Kaku Y., Yonekawa Y., Tsukahara T., and Kazekawa K. Superselective intra-arterial infusion of papaverine for the treatment of cerebral vasospasm after subarachnoid hemorrhage. J. Neurosurg. 77 (1992) 842-847
23. Kawamoto J.C., and Barrett J.N. Cryopreservation of primary neurons for tissue culture. Brain Res. 384 (1986) 84-93
24. Kean E.A., Gutman M., and Singer T.P. Studies on the respiratory chain-linked nicotinamide adenine dinucleotide dehydrogenase. XXII. Rhein, a competitive inhibitor of the dehydrogenase. J. Biol. Chem. 246 (1971) 2346-2353
25. Kubota N.K., Ohta E., Ohta S., Koizumi F., Suzuki M., Ichimura M., and Ikegami S. Piericidins C5 and C6: new 4-pyridinol compounds produced by Streptomyces sp. and Nocardioides sp. Bioorg. Med. Chem. 11 (2003) 4569-4575
26. Kumar V., Tewary D.K., Ravindranath S.D., and Shanker A. Investigation in tea on fate of fenazaquin residue and its transfer in brew. Food Chem. Toxicol. 44 (2006) 596-600
27. Langston J.W., and Ballard P. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): implications for treatment and the pathogenesis of Parkinson's disease. Can. J. Neurol. Sci. 11 (1984) 160-165
28. Langston J.W., and Ballard P.A.J. Parkinson's disease in a chemist working with 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. N. Engl. J. Med. 309 (1983) 310
29. Langston J.W., Ballard P., Tetrud J.W., and Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219 (1983) 979-980
30. Lannuzel A., Michel P.P., Höglinger G.U., Champy P., Jousset A., Medja F., Lombès A., Darios F., Gleye C., Laurens A., Hocquemiller R., Hirsch E.C., and Ruberg M. The mitochondrial complex I inhibitor annonacin is toxic to mesencephalic dopaminergic neurons by impairment of energy metabolism. Neuroscience 121 (2003) 287-296
31. Lannuzel A., Höglinger G.U., Verhaeghe S., Gire L., Belson S., Escobar-Khondiker M., Poullain P., Oertel W.H., Hirsch E.C., Dubois B., and Ruberg M. Atypical parkinsonism in Guadeloupe: a common risk factor for two closely related phenotypes?. Brain 130 (2007) 816-827
32. Mannhold R., Poda G.I., Ostermann C., and Tetko I.V. Calculation of molecular lipophilicity: state-of-the-art and comparison of log P methods on more than 96,000 compounds. J. Pharm. Sci. 98 (2008) 861-893
33. Melquist S., Craig D.W., Huentelman M.J., Crook R., Pearson J.V., Baker M., Zismann V.L., Gass J., Adamson J., Szelinger S., Corneveaux J., Cannon A., Coon K.D., Lincoln S., Adler C., Tuite P., Calne D.B., Bigio E.H., Uitti R.J., Wszolek Z.K., Golbe L.I., Caselli R.J., Graff-Radford N., Litvan I., Farrer M.J., Dickson D.W., Hutton M., and Stephan D.A. Identification of a novel risk locus for progressive supranuclear palsy by a pooled genomewide scan of 500,288 single-nucleotide polymorphisms. Am. J. Hum. Genet. 80 (2007) 769-778
34. Miller R.M., Callahan L.M., Casaceli C., Chen L., Kiser G.L., Chui B., Kaysser-Kranich T.M., Sendera T.J., Palaniappan C., and Federoff H.J. Dysregulation of gene expression in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse substantia nigra. J. Neurosci. 24 (2004) 7445-7454
35. Morikawa N., Nakagawa-Hattori Y., and Mizuno Y. Effect of dopamine, dimethoxyphenylethylamine, papaverine, and related compounds on mitochondrial respiration and complex I activity. J. Neurochem. 66 (1996) 1174-1181
36. Motulsky H., and Christopopoulos A. Fitting models to biological data using linear and nonlinear regression. Fitting models to biological data using linear and nonlinear regression (2003), A practical guide to curve fitting, GraphPad Software Inc., San Diego, CA 296-346. http://www.graphpad.com www.graphpad.com
37. Nicklas W.J., Vyas I., and Heikkila R.E. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Life Sci. 36 (1985) 2503-2508
38. Okun J.G., Lümmen P., and Brandt U. Three classes of inhibitors share a common binding domain in mitochondrial complex I (NADH:ubiquinone oxidoreductase). J. Biol. Chem. 274 (1999) 2625-2630
39. Pomper K., Lowe J., Crabtree S., and Keller W. Assessment of annonaceous acetogenin activity in pawpaw (Asimina triloba) fruit. Hortscience 42 (2007) 939
40. Przedborski S., and Vila M. The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model: a tool to explore the pathogenesis of Parkinson's disease. Ann. N.Y. Acad. Sci. 991 (2003) 189-198
41. Ramsay R.R., and Singer T.P. Energy-dependent uptake of N-methyl-4-phenylpyridinium, the neurotoxic metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, by mitochondria. J. Biol. Chem. 261 (1986) 7585-7587
42. Reichenbach H. The ecology of the myxobacteria. Environ. Microbiol. 1 (1999) 15-21
43. Rojo A.I., Cavada C., de Sagarra M.R., and Cuadrado A. Chronic inhalation of rotenone or paraquat does not induce Parkinson's disease symptoms in mice or rats. Exp. Neurol. 208 (2007) 120-126
44. Rückert G. Various corpophilic myxobacteria strains (Myxobacterales). Z. Allg. Mikrobiol. 15 (1975) 565-567
45. Schapira A.H., Cooper J.M., Dexter D., Jenner P., Clark J.B., and Marsden C.D. Mitochondrial complex I deficiency in Parkinson's disease. Lancet 1 (1989) 1269
46. Shimada H., Kozlowski J.F., and Mclaughlin J.L. The localisations in liposomal membranes of the tetrahydrofuran ring moieties of the annonaceous acetogenins, annonacin and sylvaticin, as determined by 1 H NMR spectroscopy. Pharmacol. Res. 37 (1998) 357-364
47. Shimomura Y., Kawada T., and Suzuki M. Capsaicin and its analogs inhibit the activity of NADH-coenzyme Q oxidoreductase of the mitochondrial respiratory chain. Arch. Biochem. Biophys. 270 (1989) 573-577
48. Sinz A., Matusch R., Kampchen T., Fiedler W., Schmidt J., Santisuk T., Wangcharoentrakul S., Chaichana S., and Reutrakul V. Novel acetogenins from the leaves of Dasymaschalon sootepense. Helv. Chim. Acta 81 (1998) 1608-1615
49. Smith P.D., Crocker S.J., Jackson-Lewis V., Jordan-Sciutto K.L., Hayley S., Mount M.P., O'Hare M.J., Callaghan S., Slack R.S., Przedborski S., Anisman H., and Park D.S. Cyclin-dependent kinase 5 is a mediator of dopaminergic neuron loss in a mouse model of Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 13650-13655
50. Stamelou M., Pilatus U., Reuss A., Magerkurth J., Eggert K.M., Knake S., Ruberg M., Schade-Brittinger C., Oertel W.H., and Höglinger G.U. In vivo evidence for cerebral depletion in high-energy phosphates in progressive supranuclear palsy. J. Cereb. Blood Flow Metab. 29 (2009) 861-870
51. Stamelou M., Pilatus U., Reuss A., Magerkurth J., Eggert K.M., Knake S., Ruberg M., Schade-Brittinger C., Oertel W.H., and Höglinger G.U. In vivo evidence for cerebral depletion in high-energy phosphates in progressive supranuclear palsy. J Cereb Blood Flow Metab. 29 4 (2009) 861-870
52. Swerdlow R.H., Golbe L.I., Parks J.K., Cassarino D.S., Binder D.R., Grawey A.E., Litvan I., Bennett J.P.J., Wooten G.F., and Parker W.D. Mitochondrial dysfunction in cybrid lines expressing mitochondrial genes from patients with progressive supranuclear palsy. J. Neurochem. 75 (2000) 1681-1684
53. Trojanowski J.Q., and Lee V.M. Pathological tau: a loss of normal function or a gain in toxicity?. Nat. Neurosci. 8 (2005) 1136-1137
54. Virag R. Intracavernous injection of papaverine for erectile failure. Lancet 2 (1982) 938
55. Williams D.R., and Lees A.J. Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges. Lancet Neurol. 8 (2009) 270-279